BIOPHARMA
ByCan Johnson & Johnson’s $350 Million AI Investment in 2025 Transform Drug Discovery, R&D, and Commercial Success in 2026?
Global – December 31, 2025 — Johnson & Johnson significantly expanded its use of artificial intelligence (AI) across…
AbbVie Invested $400 Million in AI in 2025: How This Will Transform Discovery, R&D, and Commercialization in 2026
Global – December 31, 2025 — AbbVie Inc. significantly expanded the integration of artificial intelligence (AI) and data-driven…
Is Eli Lilly’s $450 Million AI Investment in 2025 Set to Transform Drug Discovery, R&D, and Commercialization?
Global – December 31, 2025 — Eli Lilly and Company significantly expanded its artificial intelligence (AI) investments in…
Is Pfizer’s $500 Million AI Investment in 2025 Poised to Redefine Drug Discovery and Commercialization?
Global – December 31, 2025 — Pfizer Inc. significantly increased investment in artificial intelligence (AI) across its discovery,…
Is JPM 2026 the Moment Biopharma Finally Reset Its Strategy?
January 2026 — San Francisco | Global — The 44th Annual J.P. Morgan Healthcare Conference (JPM 2026) marked…
How Might Trump’s Strategic Healthcare Proposal Impact Innovation and Affordability?
January 22, 2026 — Global — BioNexAI Market Insights reports that U.S. President Donald J. Trump has introduced…
